A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations.
Alicja PuszkielGuilhem BousquetFrançoise Stanke-LabesqueJeanick StoccoPhilippe DecqLucie ChevillardStéphane GoutagnyXavier DeclèvesPublished in: Pharmaceutical research (2023)
Continuous icv infusion of trastuzumab at 1.0 mg/h could be an alternative dosing regimen to rapidly achieve intraventricular CSF therapeutic concentrations.